Benefit of CoQ-10 in Patients on Statins

Not Applicable

Completed

• Conditions: Soreness; Pain; Weakness; Fatigue
• Interventions: Dietary Supplement: Co-enzyme Q-10; Dietary Supplement: Placebo

• Registration Number: NCT00997269
• Lead Sponsor: Stony Brook University

Brief Summary

This study will investigate whether a supplement called co-enzyme Q10 can help ease or eliminate some of the side effects that result from taking statin medications. These side effects include muscle pain, fatigue or muscle cramping.

Detailed Description

Specific Aim 1: to demonstrate that supplementation with coQ10 in patients treated with statins ameliorates symptoms of muscle pain and fatigue and improves energy metabolism and muscle function.

This objective will be achieved in a randomized, placebo-controlled double blind trial by assessing the degree of muscle symptoms and interference of pain with daily activities, aerobic capacity, and muscle function before and after supplementation with either coQ10 or placebo in groups of statin-treated subjects.

Specific Aim 2: to examine changes at a molecular/cellular level that are associated with improved pain and muscle function in statin-treated subjects supplemented with coQ10.

This aim will be addressed by analyzing muscle biopsies taken from statin-treated patients before and after supplementation with coQ10 or placebo.

Study Timeline

• Study Start: 2009-09
• Study First Submitted: 2009-10-16
• Study First Submitted QC: 2009-10-16
• Study First Posted: 2009-10-19
• Primary Completion: 2014-07
• Study Completion: 2014-07
• Status Verified: 2016-04
• Last Update Submitted: 2016-04-28
• Last Update Posted: 2016-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

1. Adult men and women 21 years and older taking statin medications for hyperlipidemia under the current National Cholesterol Education Program guidelines (NCEP III) and complaining of myopathic symptoms.

Exclusion Criteria

1. diagnosis of cancer;
2. acute illness of any sort;
3. hemoglobin less than 12,
4. creatinine greater than 1.5 mg/dl;
5. liver dysfunction as evidenced by elevations in transaminases 3-fold higher than upper limit of normal;
6. use of certain medications or nutritional supplements within the past month;
7. untreated hypertension (diastolic BP> 100 mm HG);
8. diagnosis of diabetes mellitus (fasting blood glucose > 126 mg/dl);
9. untreated hypothyroidism;
10. overt congestive heart failure (by physical exam);
11. active inflammatory diseases such as rheumatoid arthritis, lupus, etc.,
12. bleeding disorders;
13. history of adverse reactions besides myopathy associated with the use of statins;
14. any previous adverse reaction to coQ10 or to multivitamin supplements containing coQ10;
15. plasma CPK levels > 3 times the upper normal limit; OR
16. congenital myopathies and/or neuromuscular degenerative diseases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CoQ-10 supplementation	Co-enzyme Q-10	-
CoQ-10 placebo supplementation	Placebo	-

Primary Outcome Measures

Name	Time	Method
Pain scores should be reduced	8 weeks

Trial Locations

Locations (1)

Stony Brook University GCRC; 🇺🇸 Stony Brook, New York, United States